(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN

Author(s)

Toru Imai, MD (he/him/his)

Dr
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan

Co-Author(s)

YK

Yuki Kojima, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Tatsunori Shimoi, MD, PhD

Head of Physician
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Hisaki Aiba, MD (he/him/his)

Dr
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
SY

Shu Yazaki, MD (he/him/his)

Staff physician
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
MT

Momoko Tokura, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
AK

Asuka Kawachi, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
CM

Chiharu Mizoguchi, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Hitomi S. Okuma, MD

Staff Physician
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
MA

Motoko Arakaki, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
AS

Ayumi Saito, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
SK

Syosuke Kita, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
KY

Kasumi Yamamoto, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Aiko Maejima, MD, Ph D

Staff Doctor
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Tadaaki Nishikawa, MD (he/him/his)

Staff
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
KS

Kazuki Sudo, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Emi Noguchi, MD, PhD

Physician
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
AY

Akihiko Yoshida, MD

Department of Diagnostic Pathology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
YM

Yoshiyuki Matsui, MD

Department of Urology and Retroperitoneal Surgery, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Shintaro Iwata, MD

Staff physician
National Cancer Center Hospital
Tokyo, Tokyo, Japan
EK

Eisuke Kobayashi, MD

Assistant chief
Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Akira Kawai, MD (he/him/his)

Chief, Department of Musculoskeletal Oncology and Rehabilitation Medicine
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
RU

Ryoko Udagawa, n/a

Department of Pharmacy, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Yasuhiro Fujiwara, MD, PhD (he/him/his)

Consultant Physician
Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
KY

Kan Yonemori, MD

Department of Medical Oncology, National Cancer Center Hospital
Chuo-ku, Tokyo, Japan

Objective: Trabectedin has been shown to be effective in soft tissue sarcomas (STS), particularly liposarcoma and leiomyosarcoma. Besides this direct effect on tumor cells, previous studies have shown that trabectedin has the potential to affect to immune cells in tumor microenvironment. In this study, we evaluated whether inflammatory biomarkers are predictive of efficacy of trabectedin for soft tissue sarcoma.

Methods: We reviewed retrospectively the clinical features and outcomes for STS patients treated with trabectedin between 2016 and 2020 at our institution. The neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI: neutrophil × monocyte / lymphocyte) were calculated based on blood samples taken prior to trabectedin initiation. Analyses of overall survival (OS) and progression-free survival (PFS) were performed according to various factors.

Results: Of the 101 patients identified, 54 were L-sarcoma, including 30 leiomyosarcoma and 24 liposarcoma, and 47 were other STS. Elevated SIRI, NLR, PLR, LMR and CRP were associated with a worse PFS (p = < 0.001, < 0.001, 0.025, 0.012 and < 0.001, respectively) in univariate analysis. Multivariate analysis showed that elevated SIRI, other histology and CRP were associated with poor PFS (p =0.003, 0.008 and 0.019, respectively). In addition, multivariate analysis of OS showed that SIRI was also independent prognostic factors (HR: 3.04, P=0.007).

Conclusion: This study suggests that pretreatment SIRI can be considered a biomarker for the prognostic prediction for the STS patients treated with trabectedin.